Delivra Corp (fka DLRVF)

[Renee]

DVA/DLRVF: Delivra shareholders received 0.595 common share of Harvest for each Delivra common share held.

FINRA deleted symbol:

https://otce.finra.org/otce/dailyList?viewType=Deletions

[manslap]

$$$ See you on the Harvest One board - soon $$$

[manslap]

> Dow Jones Newswires

(HRVOF HVT.V IONC.L POT.L) Move Over Craft Beer and Coffee, Cannabis Beverages Are The Next Big Thing -- CFN Media

9:02 AM ET 5/2/19 | Dow Jones


Seattle, Washington--(Newsfile Corp. - May 2, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces the publication of an article covering the exciting and emerging cannabis beverage market. The craft beer industry has experienced unprecedented growth across the United States with more than 7,000 microbreweries generating upwards of $26 billion in annual revenue, according to Statista. While these beers account for just over 10% of beer sales, those figures jump to nearly 60% when looking at the Millennial population. These same trends exist in other craft markets, such as the market for high-end coffees and teas.

The legalization of cannabis has the potential to dramatically reshape these markets. In recreational markets, such as craft beers, the infusion of tetrahydrocannabinol (THC) could create new experiences for consumers without the adverse side-effects of alcohol consumption. In wellness markets, such as craft teas, the infusion of cannabidiol (CBD) could provide a wide range of potential added benefits to support healthier lifestyles.

The cannabis industry is projected to surpass $146.4 billion by 2025, according to Grand View Research, driven by the liberalization of cannabis regulations around the world. While most of this growth has come from cannabis flower, there's no doubt that cannabis oils and concentrates are the fastest growing subset of the market. And, cannabis beverages could become the fastest growing subset of that concentrates market in short order.

Zenith Global believes that cannabis-infused beverages could become a $1.4 billion market by 2023-up from just $89 million last year. Cannabis infused beers and teas are just the beginning-THC and CBD are being infused into sodas, ciders, wines, spirits and even bottled water with concentrations ranging from 2.5 milligrams to more than 100 milligrams. Many of these products are already on the market in the United States where legal.

Growing Interest in the Space

Many large beer companies were unprepared for the rise of craft beer, but beverage giants aren't about to make the same mistake with cannabis. While the alcohol industry has already made sizable investments and inroads into the industry, non-alcoholic beverage companies are increasingly taking a look at CBD-infused products as a way to target the rapidly growing functional beverage subset of the market.

Coca-Cola Co. was rumored to be in talks to acquire a line of CBD-infused beverages in the recent past. While the company decided to hold off for now, the decision to remove hemp from the Controlled Substances list could open the door once again. Hemp-based CBDs could enjoy more widespread adoption without these onerous regulations and ultimately open the door to more mainstream availability.

On the recreational side of the business, Constellation Brands Inc. invested more than $4 billion into Canopy Growth Corp. in exchange for a 38% equity stake with warrants capable of bringing the total to more than 50%. Molson Coors Brewing Co. and Heineken NV also made strategic acquisitions and partnerships in the emerging cannabis space ahead of these trends.

Investing in Cannabis Beverages

There are many different companies focused on cannabis-infused beverages for both recreational and wellness purposes.

Weekend Unlimited Inc. (CSE: POT) (FSE: 0OS1)(OTCQB: WKULF) acquired Verve Beverage Company earlier this year to enter the emerging cannabis-infused beverage space. In addition to Verve Energy, the Company has developed a premium CBD infused energy drink line under the CHAMP brand, which will be targeted to active audiences. In alignment with those audiences CHAMP Energy is the official energy drink of the San Jose Sharks. Verve energy has strong brand awareness with previous widespread distribution across North America that generated $236 million in direct-to-consumer sales. The portfolio's market recognition and positioning could provide a durable competitive advantage in the lucrative functional beverage space.

Last year Harvest One Cannabis Inc. (TSXV: HVT) (OTCQX: HRVOF) acquired Dream Water and Dream Water Canada, which has developed a natural, 2.5oz, 0-calorie, liquid sleep shot that's sold online and in over 30,000 North American retail outlets including Shoppers Drug Mart, Walmart and Kroger. The company has already begun formulation work on a CBD-infused version of the product that's designed to promote a wide range of potential benefits, such as pain relief and anti-anxiety effects. These products would leverage the same distribution channels that already exist.

Please click here to receive an investor deck and corporate updates on Harvest One Cannabis Inc.

Ionic Brands Corp. (CSE: IONC) recently entered the cannabis-infused beverage space with two highly sought-after coffee and tea patents. The two patents enable the production of ISO-certified products that are tasteless, 100% water soluble, and capable of hosting THC and CBD compounds. These attributes are ideal for the craft coffee and tea market, which already generate billions in annual sales around the world. Single-serve coffee could be an especially compelling target for companies in the space.

What's Next?

Cannabis-infused beverages are likely to experience significant growth over the coming years. With many new startups entering the space, there's a significant opportunity for investors to capitalize on these growth rates as many larger companies begin to look more closely at acquisitions and partnership deals in the space. These could become major catalysts for investors over the coming quarters.

Please follow the link to read the full article: https://www.cannabisfn.com/move-over-craft-beer-and-coffee-cannabis-beverages-are-the-next-big-thing...

About CFN Media

For Visitors and Viewers

CFN Media's Cannabis Financial Network (CannabisFN.com) is the destination for savvy investors and business people profiting from the worldwide cannabis industry. Viewers will see breaking news, exclusive content and original programming involving the people, companies and investments shaping the industry.

For Cannabis Businesses & Companies

CFN Media is a leading agency and financial media network dedicated to the cannabis industry. We help private, pre-public and public cannabis companies in the US and Canada attract capital, investors and media attention.

Our powerful digital media and distribution platform conveys a company's message and value proposition directly to accredited and retail investors and national media active in the North American cannabis markets.

Since 2013, CFN Media has enabled the world's preeminent cannabis companies to thrive in the capital and public markets.

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/featuredcompany

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on http://www.cannabisfn.com (the 'Site') is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

Contact

CFN Media

Frank Lane

206-369-7050

[e-mail]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/44487

> Dow Jones Newswires

May 02, 2019 09:02 ET (13:02 GMT)

[manslap]

The Information Circular, Notice, Proxies and Letter of Transmittal is being mailed to shareholders (May 1st).

The Shareholder Meeting will be held on May 24th at 10 a.m.

[Maximum7]

mid april/may/ 2nd quarter it looks like.. will this be a sound decision to buy now or just buy more harvest one?

[Maximum7]

When would delivra shares convert to harvest one?

[manslap]

I jump in dlrvf for $50,000

[manslap]

https://seekingalpha.com/article/4248236-harvest-one-cannabis-highly-undervalued-cannabis-stock

[Wo]

Harvest One Acquires Delivra to Strengthen its Medical and Wellness Division

https://finance.yahoo.com/news/harvest-one-acquires-delivra-strengthen-134900532.html?.tsrc=applewf

CNW Group
March 4, 2019, 8:49 AM EST
TORONTO , March 4, 2019 /CNW/ - Harvest One Cannabis Inc. (TSXV: HVT, OTCQX: HRVOF – "Harvest One") and Delivra Corp. (TSXV: DVA – "Delivra") are pleased to announce today that they have entered into a definitive arrangement agreement (the "Arrangement Agreement") pursuant to which Harvest One will acquire all of the issued and outstanding common shares of Delivra (the "Delivra Shares") (the "Transaction"). Under the terms of the Arrangement Agreement, shareholders of Delivra ("Delivra Shareholders") will receive 0.595 common shares of Harvest One (the "Harvest One Shares") for each Delivra Share (the "Exchange Ratio").

[manslap]

Call me Crazy I'm in for $30,000 DLRVF

[Wo]

Delivra Publishes Positive Results Utilizing its Unique Platform Technology for Topical Doxycycline

https://finance.yahoo.com/news/delivra-publishes-positive-results-utilizing-120000645.html?.tsrc=applewf

CNW Group
February 6, 2019, 7:00 AM EST
TORONTO , Feb. 6, 2019 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") today announced the publication of positive data from a laboratory and clinical study demonstrating the stability, safety and efficacy to treat diabetic wounds, using Delivra's platform technology, to deliver a topical version of the prescription drug, doxycycline. These results were published in the respected peer-reviewed scientific journal, Wounds Research. This article may be found at the following link: https://www.ncbi.nlm.nih.gov/pubmed/30664497.

A large number of diabetics will develop diabetic leg wounds, which could cause amputation and other complications, which could ultimately result in death. With the aging populations in Canada , USA and Europe , diabetes is becoming a significant problem and is a highly unmet need in medicine today. Delivra continues its significant work in the diabetic field to address this important and growing need.

"This impressive data further validates Delivra's novel technology and offers doctors and their patients an effective, safe and convenient cream for diabetic wounds, without the side effects of oral doxycycline. With a robust pharmaceutical pipeline of high-value innovative products, Delivra-doxycycline formulation provides a unique and growing commercialization opportunity. As such, we will continue to pursue out-licensing opportunities for major global markets to unlock the value of our unique portfolio," said Dr. Joseph Gabriele , CEO of Delivra.

Delivra has filed a provisional patent to protect its unique formulation using doxycycline. DelivraTM topical doxycycline is currently available by prescription across Canada through the compound pharmacy services of NKS Health Ltd.

[ADVFN_bioking]

going up day after day but its still under radar once it get discovered then $3+ will come quickly

[manslap]

I jump in dlrvf for $12,000

[GELDTEAM]

Cool thanks for the feedback tho I will man thanks

[ADVFN_bioking]

DVA.V and DLRVF both ticker are from Delivra ..do your own dd and then decide

[GELDTEAM]

So both symbols are the same company it's this a good price go buy in then or wait some say it might drop to .10-15 before going up ?

[ADVFN_bioking]

in usa the currenncy is $ and in canada its C$ which has lower value that US$ .

[GELDTEAM]

Are they both the same company ? But USA market because one it's .29 and the other .38 and the volume it's way different thanks for the feedback

[GELDTEAM]

How can u buy from USA?

[ADVFN_bioking]

only listing is on TSXV ticker is DVA

[GELDTEAM]

So buy now or what E-TRADE doesn't show the bid or ask

[ADVFN_bioking]

Marktcap $16 million apure joke for this company but it wont stay for long at this price

[BioSpecialist]

once it gets noticed then this one will explode because of its low float

[manslap]

OTC DLVRF - Boom

[ADVFN_bioking]

Partner Deal(s) news is imminent which means upfront payments for DVA .Market Cap of C$ 15 million is a PURE GIFT !

Delivra Receiving Interest for its Expertise and Technology for Use in the Cannabis and Pharma Industries
https://finance.yahoo.com/news/delivra-receiving-interest-expertise-technology-110000081.html

TORONTO , Oct. 1, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company"), a scientific and biotechnology company, today announced that it has recently received inquiries from a number of interested parties in relation to the Company's proprietary transdermal delivery system platform, including its proprietary applications for the cannabis and pharma industries.

[BioSpecialist]

Major breakout to $1+ possible especially on good news like partner deals which could happen anytime now .

Delivra Receiving Interest for its Expertise and Technology for Use in the Cannabis and Pharma Industries
https://finance.yahoo.com/news/delivra-receiving-interest-expertise-technology-110000081.html

Delivra Corp. (TSXV: DVA - "Delivra" or the "Company"), a scientific and biotechnology company, today announced that it has recently received inquiries from a number of interested parties in relation to the Company's proprietary transdermal delivery system platform, including its proprietary applications for the cannabis and pharma industries.

As a result of these inquiries, the Company has engaged Canaccord Genuity Corp. to act as exclusive financial advisor to identify, review, analyze and explore the range of strategic and other opportunities available to the Company within the cannabis and pharma industries.

[BioSpecialist]

the cheapest cannabis play you can get at this time

[BioSpecialist]

nice takeover candidate

[BioSpecialist]

will do some research on it

[BioSpecialist]

hmm not bad

[Wo]

Delivra publishes positive results utilizing its novel platform technology for Varicose Veins

https://finance.yahoo.com/news/delivra-publishes-positive-results-utilizing-120000097.html?.tsrc=applewf


CNW Group
January 8, 2019, 7:00 AM EST
TORONTO , Jan. 8, 2019 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") today announced the publication of positive data from a clinical study demonstrating the safety and efficacy to treat chronic venous insufficiency of lower limbs, using the LivReliefTM Varicose Vein Cream over-the-counter product. These results were published in the respected peer-reviewed scientific journal, PLOS ONE. This article may be found at the following link: https://doi.org/10.1371/journal.pone.0208954.

In a human clinical setting, undertaken by an independent third-party medical clinic, LivReliefTM Varicose Vein Cream provided significant therapeutic improvement in the treated lower limbs after six weeks of treatment. In the study, LivReliefTM Varicose Vein Cream was tested in humans with severe lower limb pain. This exemplifies Delivra's unique technology, with its multi-laminar systems which is capable of gradually releasing the active ingredient to the area of need, yielding quicker and longer lasting relief.

"This impressive data further validates Delivra's platform technology, offering patients an effective, safe and convenient over-the-counter cream for varicose vein treatment. Our robust over-the-counter product development and pharmaceutical pipeline of high-value innovative products provide an array of unique commercialization opportunities. LivReliefTM Varicose Vein Cream, along with LivReliefTM Pain Relief Cream, LivReliefTM Extra Strength Chronic Angry Pain Relief Cream and LivReliefTM Sports & Active Pain Relief Cream can be found in over 6,000 retail outlets across Canada ," said Dr. Joseph Gabriele , CEO of Delivra.

[Wo]

I’m pained to say I almost agree with your sentiments and have reverted to a majority ‘Hope’ position. I’ve been searching for the silver lining in this Dark cloud, through the financials, management strategy and IP. The IP I think presents the greatest value, but the execution is...

Patiently waiting.

[Cant lose]

Stay away! So bad that the insiders wont even buy. CEO is inexperienced and failing badly. The board has done nothing and so many have lost their hard earned money. Bobby Orr, MJ pump and dump releases all smoke and mirrors. 0.10 here we come.

[Wo]

Delivra publishes positive results using its platform technology for topical Advil™ (ibuprofen) and Celebrex™ (celecoxib)

http://www.stockhouse.com/news/press-releases/2018/12/17/cgx-energy-announces-definitive-rig-agreement-for-use-of-the-ralph-coffman-rig

CNW Group
December 11, 2018, 8:00 AM AST
TORONTO , Dec. 11, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") today announced the publication of positive data from a pre-clinical study demonstrating the safety and efficacy to treat pain directly with a topical version of Advil™ (ibuprofen) and Celebrex™ (celecoxib). Testing for effects on joint pain and inflammation; topical Delivra-ibuprofen and Delivra-celecoxib formulations offer sustained long-term pain and swelling reduction, compared to oral equivalents. These results were published in the respected peer-reviewed scientific journal, Journal of Pain Research, under the title, "Penetration and efficacy of transdermal NSAIDs in a model of acute joint inflammation". The article may be found at the following link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6239099/?report=reader

In pre-clinical testing, undertaken by an independent third-party research organization, the Delivra-ibuprofen and Delivra-celecoxib formulations provided sustained pain reduction. In the study, both Delivra formulations were tested in an acute dog model of arthritis where the formulation performed equally or better for swelling and pain reduction compared its oral equivalent and test controls. This exemplifies Delivra's technology, with its multi-laminar system, is capable of gradually releasing the active ingredient to the area of need. This transdermal, designed "slow release" is a valuable and highly advantageous characteristic of the topical Delivra-ibuprofen and Delivra-celecoxib creams and may offer significant advantages over oral medication. These formulations will provide better localization of the drug at the site of need, yielding quicker and longer lasting relief.

"This impressive data further validates Delivra's platform technology by outperforming oral delivery and offering patients an effective, safe and convenient cream for pain management. Our robust pharmaceutical pipeline of high-value innovative products, including Delivra-ibuprofen and Delivra-celecoxib formulations, provide an array of unique commercialization opportunities. As such, we will continue to pursue out-licensing opportunities for major global markets to unlock the value of our portfolio," said Dr. Joseph Gabriele , CEO of Delivra.

For these two formulations, the Company has two PCT patent pending applications.

[Wo]

View from the C-Suite: Dr. Joseph Gabriele, Chief Executive Officer, Delivra Corp., tells his company's story. Filmed on November 27, 2018

https://finance.yahoo.com/news/view-c-suite-dr-joseph-174300972.html?.tsrc=applewf

[Wo]

Delivra Achieves Record Third Quarter 2018 Revenues
CNW Group
CNW GroupNovember 19, 2018, 7:00 AM EST

https://finance.yahoo.com/news/delivra-achieves-record-third-quarter-120000789.html?.tsrc=applewf

TORONTO , Nov. 19, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") reported its financial results for the three and nine months ended September 30, 2018 . All figures are reported in Canadian dollars ($), unless otherwise indicated. Delivra's financial statements are prepared in accordance with International Financial Reporting Standards.

Highlights for the Third Quarter and Year-To-Date 2018:

Achieved record revenues of $1,670,077 for the quarter and $3,976,861 for the year-to-date, representing an 81% and 21% growth over the comparative periods, respectively;

Successfully launched two new LivReliefTM products during the quarter which have begun selling on retailer shelves, LivReliefTM Extra Strength Chronic Angry Pain Relief Cream and LivReliefTM Sports & Active Pain Relief Cream;

Re-branded and re-packaged the LivReliefTM family of products during the quarter, which is now available at retail stores;

Increased the number of retail locations currently selling LivReliefTM products from 5,200 stores at the beginning of the year to over 6,000 retail locations as of today;

Developed a revolutionary, proprietary topical cream base therapeutic, DelivraTMN, for molecules of cannabis, cannabis-like and opioids, for a safer more targeted and consistent delivery to patients afflicted with chronic pain and anxiety;

Positive results received on the ability to treat pain directly with a topical version of AdvilTM (ibuprofen). Testing for effects of joint pain and inflammation, topical Delivra-ibuprofen formulation offers long-term pain and swelling reduction compared to oral ibuprofen;

Signed a joint venture agreement with Intervivo Solutions for a ready to market sleep and anti-anxiety topical therapeutic cream for the animal health industry. Our expertise in formulation using our innovative delivery system platform combined with Intervivo's success in demonstrating pharmacokinetic, safety and efficacy data in clinically relevant canine and feline models provides a unique platform for rapid development of transdermal commercial products for the veterinary market;

Founder and CEO, Dr. Joseph Gabriele , received the Ernst & Young Entrepreneur of the Year 2018 Ontario award in the Health Care category; and

Due to recently received inquiries from a number of interested parties in relation to the Company`s proprietary transdermal delivery system platform, Delivra engaged Canaccord Genuity Corp. to act as exclusive financial advisor to review, identify, analyze and explore the range of strategic and other opportunities available to the Company within the cannabis and pharma industries. There can be no assurance that the Company will enter into any transaction, that there will be any change in the operation or ownership of the Company, or that the Company will take any other corporate action as a result of the review.

[Wo]

Ernst & Young Names Dr. Joseph Gabriele of Delivra - Entrepreneur of the Year 2018 Ontario Award in the Health Care Category

CNW Group
October 30, 2018, 7:00 AM EDT
TORONTO , Oct. 30, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company"), a science and biotechnology company, today announced that its Founder and CEO, Dr. Joseph Gabriele , is the recipient of the Ernst & Young Entrepreneur Of The Year 2018 Ontario award in the Health Care category.

https://finance.yahoo.com/news/ernst-young-names-dr-joseph-110000102.html?.tsrc=applewf

"I'm humbled and honoured by the award", said Joseph Gabriele . "I'm grateful to the Delivra team who are the true heroes. I'm proud that EY has recognized the capabilities of our unique patented delivery system, DelivraTM, for pharmaceutical and natural molecules across a spectrum of medical and consumer products capabilities. Delivra was born out of a need to help my wife who was debilitated by post-surgery pain, hence the genesis of our novel topical solution. She feared the addictive powers of opioids and couldn't take oral medications due to digestive challenges. Today, Delivra helps many pain suffers in Canada and internationally. We also have an over-the-counter product line, called LivReliefTM, and just launched a new Extra Strength Chronic Angry Pain cream, as well as a unique new Sports & Active cream. In our pharmaceutical division, we are helping patients that are suffering with pain related to medical issues, including diabetes, and we have the capability of delivering cannabis and CBD to both humans and animals, topically and effectively. Our mission is to help pain sufferers reclaim their lives back. We are excited about the future and our proven capability and potential to help millions of people."

"Companies in the health care sector face a challenging and competitive landscape," says Paula Smith , EY Entrepreneur Of The Year Ontario Program Co-Director. " Canada , in particular, has an aging population and growing demand for patient care, pushing entrepreneurs to respond quickly and thoughtfully with innovative solutions to meet changing needs."

"Delivra is doing just that," adds Elena Doucette , EY Entrepreneur Of The Year Ontario Program Co-Director. "They're revolutionizing the delivery of pain relief, and doing it in a safer and more effective way for those in need. We're proud to have recognized the outstanding work Joseph is doing in the health care sector."

ABOUT DELIVRA CORP.

Delivra Corp. is a specialty biotechnology company having a proprietary transdermal delivery system platform that can shuttle pharmaceutical and natural molecules through the skin, in a targeted manner. Delivra manufactures and sells a growing line of natural topical creams with the proprietary transdermal delivery system platform under the LivReliefTM brand, for conditions such as joint and muscle pain, nerve pain, varicose veins, wound healing, and under the LivSportTM brand for sports performance. LivReliefTM products are available in pharmacies, grocery chains, and independent health food stores across Canada , including, but not limited to, Shoppers Drug Mart, Walmart, Loblaw, Rexall, Pharmasave, London Drugs, and on-line at www.livrelief.com. In parallel with its consumer products business, Delivra also has a mandate to license its patent-pending, proprietary transdermal delivery technology platform to pharmaceutical companies globally, for the repurposing of pharmaceutical molecules transdermally to treat a broad range of conditions, along with licensing its over-the-counter products globally. Delivra is headquartered in Hamilton, Ontario and has a research and development laboratory in Charlottetown, Prince Edward Island .

Further information on Delivra can be found at www.delivracorp.com and www.livrelief.com.

About EY Entrepreneur Of The Year®

EY Entrepreneur Of The Year® is the world's most prestigious business awards program for entrepreneurs. The program makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global awards program of its kind, Entrepreneur Of The Year celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 145 cities in more than 50 countries. ey.com/ca/EOY

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Delivra Corp



View original content: http://www.newswire.ca/en/releases/archive/October2018/30/c6811.html

[Wo]

Delivra Announces Stock Option Grant and Postponement of Warrant Expiry

CNW Group
October 15, 2018, 5:00 AM MDT
TORONTO , Oct. 15, 2018 /CNW/ -

https://finance.yahoo.com/news/delivra-announces-stock-option-grant-110000467.html?.tsrc=applewf

Delivra Corp. (TSXV: DVA - "Delivra" or the "Company"), a scientific and biotechnology company, today announced that it has issued an aggregate of 550,000 incentive stock options (the "Options") each exercisable into one common share in the capital of the Company, to eligible participants under the Company's incentive stock option plan (the "Plan"). The Options are exercisable at $0.36 per share for a period of five years from the date of grant, expiring on October 15, 2023 . Of the Options granted, 500,000 vest immediately and 50,000 vest 50% on the first anniversary of the grant date and 50% on the second anniversary of the grant date. The options have been granted under and are governed by the terms of the Plan.

The Company also makes reference to the 700,000 share purchase warrants, exerciseable between $0.60 and $0.61 per share, expiring on October 31, 2018 . Pursuant to the terms of the warrants, the warrant expiry date has been postponed until the third business day following the lifting of the "blackout period" that will be in effect on October 31, 2018 in connection with the release of the Company's September 30 th, 2018 financial results.

[Wo]

Delivra Receiving Interest for its Expertise and Technology for Use in the Cannabis and Pharma Industries

https://finance.yahoo.com/news/delivra-receiving-interest-expertise-technology-110000081.html?.tsrc=applewf

CNW Group
October 1, 2018, 5:00 AM MDT
TORONTO , Oct. 1, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company"), a scientific and biotechnology company, today announced that it has recently received inquiries from a number of interested parties in relation to the Company's proprietary transdermal delivery system platform, including its proprietary applications for the cannabis and pharma industries.

As a result of these inquiries, the Company has engaged Canaccord Genuity Corp. to act as exclusive financial advisor to identify, review, analyze and explore the range of strategic and other opportunities available to the Company within the cannabis and pharma industries. There can be no assurance that the Company will enter into any transaction, that there will be any change in the operation or ownership of the Company, or that the Company will take any other corporate action as a result of the review.

Delivra has not set a timetable for completion of the review process and it does not intend to disclose further developments with respect to the review unless and until required by law or until such disclosure is deemed appropriate by the Company. Delivra cautions that there are no guarantees that the process will result in a transaction of any kind, and if a transaction is undertaken, that there is no guarantee as to its terms or timing.

[Wo]

DVA trades down to 14.24m CAD today/0.30 CAD. I am looking to buy in these Murky 52 week low and low volume areas. I must admit, the low volume (78k today, 43k avg) scares me. Seems many are on their way out.

[Wo]

Bear Market on DVA. Support seems to be around 15 million market Cap. At .33 and lower, starts to show more value